In 2021, the FDA approved a third semaglutide formulation, Wegovy, for chronic weight management for those with obesity or overweight and at least one weight-related condition
J Endocrinol Invest 42:6173 Eckard AR, Wu Q, Sattar A et al (2024) Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial
However, to include alcohol in your diet as you pursue weight management, consider these tips: Choose lower-calorie alcoholic drinks made with little to no added sugar
The medication's weight loss effects can improve hepatic steatosis and inflammation, making it a potentially valuable treatment option for this population
To calculate exact volumes, use our free Peptide Reconstitution Calculator